The CEO of Sweden-based healthtech startup Tandem Health said it is “very difficult” for US competitors to compete against Tandem Health in Europe, amid a push from European healthcare providers to work with European businesses.
Speaking on the Tech.eu podcast, Lukas Saari, Tandem co-founder, said: “We have very much taken the full European focus, we are a full-on European company.
“Everyone is based here; we only have European-based investors. I think this has helped us a lot in many of the discussions and that it would be very difficult for the US-based competitors to come into Europe and compete.”
Saari’s comments come amid a push from some European tech leaders and politicians to become less reliant on US tech amid fluctuating relations with President Trump.
Saari has previously said that in procurement, European governments and public services increasingly prefer working with European businesses.
Tandem, which is powered by LLMs, offers clinicians an AI co-pilot that generates medical notes during patient consultations.
Tandem’s co-pilot has evolved from solving the niche use case of medical note taking, expanding to a full medical assistant, which now includes referral notes and patient communications before, during and after patient visits.
In July last year, Tandem raised $50 million in a Series A round after a $10m seed round in 2024. Its investors include Kinnevik and Northzone.
Tandem, which employs around 170 people, is focused on the European market, with the UK, where NHS clinicians use it, being its biggest market in terms of user numbers.
Elsewhere in the podcast, Saari discusses Tandem’s use of LLMs, the possible threat from AI giants to its business, as well as Tandem’s future plans.
Would you like to write the first comment?
Login to post comments